國藥新冠疫苗獲准向內地3至17歲兒童及青少年接種
中國疾控中心研究員、科研攻關組疫苗研發專班專家組成員邵一鳴周五(11日)表示,經國家有關部門的批准,國藥中生北京所和北京科興中維公司的新冠疫苗,在有需要的情況下可用於3至17歲人群的疫苗接種。
邵氏稱,國藥中生北京所和北京科興中維公司研製的滅活疫苗在獲得附條件上市批准以後,繼成人使用之後,繼續開展了3至17歲人群的擴大臨床試驗,積累了更多的數據,這些數據及時上報國家,經過專家的認真審評論證,充分證明在3至17歲這個人群是安全的。
此前科興新冠滅活疫苗在內地的緊急使用年齡從18歲以上擴大至3歲以上。據國家衛健委數據顯示,截至6月10日,內地累計報告接種新冠病毒疫苗8.45億劑次,當日增加2,044.3萬劑次。
邵一鳴補充,內地新冠疫苗使用人群最先是在18歲以上的成人開始的,現在成人接種最大年齡超過100歲,累計已經接種了8億多劑次,也是國際上單個國家接種劑次最多的。在這些大規模接種當中,大量數據證明了中國的新冠疫苗是安全和有效的。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.